MNST enters the back half of May on a strong footing, with last week's earnings beat still propelling the stock and analysts racing to revise targets upward — but the price is now sitting within a whisker of consensus, raising the question of how much runway remains.
The stock closed at $87.09 on Friday, up 16% over the past month. That move was largely driven by a single catalyst: Q1 results released on May 7 sent shares up nearly 12% in one session, a gain that held through the five-day window. The stock is now up roughly 12% year-to-date. RSI14 is running at 73, technically overbought territory, and the stock is pressing into the upper band of its recent range.
The analyst response to the earnings beat was swift and broad. Multiple firms raised targets in the days immediately after results. Evercore ISI pushed its Outperform target to $95, up from $90. RBC Capital lifted to $88, keeping an Outperform. Wells Fargo went to $87 on an Overweight. JP Morgan raised to $83 from $78, staying at Neutral. UBS moved to $84 from $80, also Neutral. Rothschild upgraded outright — from Neutral to Buy — with a target of $90. The direction of travel is unambiguous: virtually every desk that touched the stock raised its number. Yet the consensus mean price target of $88.24 is only marginally above Friday's close of $87.09, leaving a return potential of just 1.3%. The Street has largely caught up to the price.
Bulls argue Monster's leadership in energy drinks, its Coca-Cola distribution partnership, and new product launches give the business durable growth levers. Bears counter that the category faces growing regulatory scrutiny, international performance continues to trail Red Bull, and a PE of 35.8x with an EV/EBITDA of 26.2x leaves little room for disappointment. The analyst recommendation differential factor ranks at the 98th percentile — an unusually wide gap between the most bullish and most cautious views on the Street — which underscores the genuine disagreement on valuation versus growth.
Short positioning tells a relaxed story. SI as a percentage of free float has been drifting lower through April and May, coming in at 2.9% of the float on May 14, down from a recent peak near 3.3% in mid-April. That six-week decline accelerated after earnings, as shorts covered into the rally. Borrowing costs are minimal at 0.33% annualised, and availability remains wide — over 1,000% of short interest — meaning there is ample room to borrow and no squeeze pressure whatsoever. The ORTEX short score of 35.3 is mid-range, consistent with a stock where shorts are present but not particularly convicted.
Options positioning is likewise unexceptional. The put/call ratio of 1.15 is fractionally below its 20-day average of 1.16, with a z-score of -0.35 — essentially neutral. There is no unusual demand for downside protection and no aggressive bullish positioning either. The 52-week PCR range runs from 0.84 to 1.86, and the current reading is near the calm middle of that band. By comparison, close peer CELH fell 6.6% on the week while KO added 3.1% — Monster's 0.9% weekly gain was the quiet middle of the beverage complex.
The most notable ownership feature is the Coca-Cola anchor: KO holds 20.9% of Monster's shares, a stake unchanged since at least December 2024. BlackRock added 1.9 million shares as of April 30 and Capital Research added nearly 700,000 — both modest additions that point to passive index flows rather than active accumulation. Insider activity from March showed the Chairman and Co-CEO each sold around 137,000 shares at $77.11, well below the current price, suggesting those sales were routine plan transactions at a time when the stock was cheaper.
With no next earnings date confirmed and the stock sitting barely above consensus target, the key watch point is whether analysts begin to revise targets above $90 or whether the stock's proximity to fair value draws fresh short interest back into the float.
See the live data behind this article on ORTEX.
Open MNST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.